AC-193 is an experimental monoclonal antibody developed by Acumen Pharmaceuticals that represents a next-generation approach to anti-amyloid therapy for Alzheimer's disease[@potter2024]. Unlike previous antibodies that target either amyloid-beta monomers or plaques, AC-193 is specifically designed to bind to and neutralize soluble toxic amyloid-beta oligomers (AβOs), which are widely considered to be the primary neurotoxic species responsible for synaptic dysfunction and memory impairment in Alzheimer's disease[@demattos2024][@selkoe2011].
This selective targeting approach is based on the oligomer hypothesis of Alzheimer's disease, which posits that soluble, diffusible Aβ oligomers are the key pathogenic agents, rather than the insoluble amyloid plaques that have historically been the focus of therapeutic development[@lambert1998][@walsh2002].
The oligomer hypothesis emerged from observations that amyloid plaques alone do not correlate well with cognitive impairment[@krafft1989]. Key discoveries that shaped this hypothesis include:
-
Toxicity of soluble oligomers: Lambert et al. (1998) demonstrated that naturally secreted Aβ oligomers were potent neurotoxins at picomolar concentrations, even without plaque formation[@lambert1998].
-
Inhibition of LTP: Walsh et al. (2002) showed that soluble AβOs potently inhibited hippocampal long-term potentiation (LTP), a cellular correlate of learning and memory[@walsh2002].
-
Pathological correlation: Studies found that soluble Aβ levels correlate better with cognitive impairment than plaque burden in human brain tissue[@haass2012].
-
Mechanistic studies: AβOs bind to synapses, causing spine loss and dysfunction through multiple mechanisms[@benilova2010][@hill2008].
¶ Oligomer Structure and Toxicity
Aβ oligomers exist in multiple forms with varying degrees of toxicity[@roychaudhuri2013][@ivanova2021]:
- Dimers: The smallest toxic species, sufficient to impair LTP
- Trimers/Tetramers: Intermediate oligomers with enhanced toxicity
- Protofibrils: Larger soluble aggregates, highly toxic
- Fibrils: Insoluble, less directly toxic but can serve as reservoir
The toxic mechanisms include:
- Direct synaptic binding and internalization
- NMDA receptor dysfunction[@li2012]
- Calcium homeostasis disruption
- Mitochondrial dysfunction
- Oxidative stress
- Inflammation
AC-193 is designed with high specificity for soluble Aβ oligomers, with minimal binding to monomers or plaques[@potter2024]. This selectivity is achieved through:
- Conformational targeting: The antibody recognizes a conformational epitope present in oligomeric but not monomeric Aβ
- Epitope mapping: Specific N-terminal and central region sequences unique to oligomers
- Structural preference: Preference for the β-sheet-rich structure of oligomers
Once bound, AC-193 provides neuroprotection through multiple pathways[@demattos2024][@leknine2013]:
- Neutralization: Antibodies bind AβOs, preventing their interaction with neuronal receptors
- Synaptic protection: Blockade of AβO binding to synapses preserves dendritic spine density
- F clearance: Engagement of peripheral immune system for antibody clearance
- Inflammation modulation: Reduced microglial activation secondary to decreased oligomer burden
| Antibody |
Company |
Target |
Specificity |
Status |
| Lecanemab |
Biogen/Eisai |
Aβ monomers + protofibrils |
Moderate |
Approved |
| Donanemab |
Eli Lilly |
N-terminal Aβ (plaques) |
Moderate |
Approved |
| Crenezumab |
Roche |
Aβ oligomers + plaques |
Moderate |
Phase 3 |
| AC-193 |
Acumen |
Soluble Aβ oligomers |
High (selective) |
Phase 1 |
AC-193's selectivity differentiates it from approved antibodies that target either monomer/protofibrils (lecanemab) or plaques (donanemab)[@swanson2023][@mintun2021].
Preclinical characterization demonstrated[@potter2024]:
- High affinity for soluble AβO (sub-nanomolar)
- Minimal binding to Aβ monomers (1000-fold selectivity)
- Negligible binding to amyloid plaques
- Protection against AβO-induced synaptic toxicity in neuronal cultures
Animal models showed[@acumen2024]:
- Reduction in brain AβO levels
- Preservation of synaptic markers
- Improvement in cognitive behavioral paradigms
- No ARIA (amyloid-related imaging abnormalities)
- Favorable brain pharmacokinetics
Key mechanistic studies established:
- AβO-induced synaptic loss is reversible[@mucke2011]
- Early intervention provides maximum benefit[@tomiyama2010]
- Clearance of oligomers is sufficient for functional recovery
AC-193 is currently being evaluated in a first-in-human Phase 1 study[@potter2024]:
Study Design:
- First-in-human, dose-escalation
- Healthy volunteers and patients with early AD
- Single and multiple ascending doses
Primary Endpoints:
- Safety and tolerability
- Pharmacokinetics
- Immunogenicity
Secondary Endpoints:
- Target engagement biomarkers
- CSF AβO levels
- Pharmacodynamic markers
Based on the selective mechanism, AC-193 is positioned for development in[@demattos2024]:
- Early Alzheimer's disease: Patients with mild cognitive impairment (MCI) due to AD or early-stage AD
- Prevention trials: Preclinical AD in biomarker-positive individuals
- Combination therapy: Potential combination with other disease-modifying agents
| Property |
Expected Value |
| Administration |
Intravenous infusion |
| Dosing |
Monthly or quarterly |
| Half-life |
3-4 weeks (typical IgG1) |
| Brain penetration |
Moderate (peripheral sink) |
| CSF exposure |
To be determined |
- Target engagement: Reduction in soluble CSF AβO
- Biomarker effects: Preservation of synaptic markers
- Plaque effects: Minimal (selective for oligomers)
The oligomer-selective mechanism may provide safety advantages:
- Reduced ARIA risk: Less plaque binding may reduce amyloid-related imaging abnormalities compared to plaque-targeting antibodies
- No plaque mobilization: Doesn't cause soluble Aβ release from plaques
- Peripheral clearance: Antibody-AβO complexes cleared peripherally
Phase 1 will assess:
- Infusion reactions
- Immunogenicity
- MRI changes (ARIA monitoring)
- Cognitive endpoints
Soluble AβOs are the most relevant therapeutic target because[@cullen2022]:
- Direct toxicity: Cause synapse loss and neuronal dysfunction
- Early appearance: Appear before plaques in disease progression
- Reversible: Synaptic damage is reversible if oligomers removed
- Correlation: Levels correlate with cognitive impairment
Targeting oligomers provides advantages:
- Earlier intervention possible (before plaques form)
- May preserve function even after plaques develop
- Could be combined with plaque-targeting approaches
¶ Competitive Landscape
| Drug |
Target |
Company |
Approval |
| Lecanemab |
Aβ protofibrils |
Biogen/Eisai |
2023 |
| Donanemab |
Aβ plaques |
Eli Lilly |
2024 |
| AC-193 |
Aβ oligomers |
Acumen |
Phase 1 |
AC-193 differentiates from approved drugs through:
- Higher selectivity: Pure oligomer targeting vs. broader specificity
- Different mechanism: Neutralization vs. plaque removal
- Safety profile: Potentially reduced ARIA risk
- Soluble AβO quantification in CSF/plasma
- Synaptic markers (neurogranin, SNAP-25)
- Tau biomarkers
- Neuroimaging (PET, MRI)
- With anti-tau therapies
- With disease-modifying agents
- With symptomatic treatments
- Early intervention in prodromal AD
- Genetic risk carriers (APOE4)
- Biomarker-positive preclinical populations
- Potter et al., AC-193: a selective amyloid-beta oligomer antibody for Alzheimer's disease (2024)
- Demattos et al., Anti-Aβ oligomer antibodies as therapeutic agents (2024)
- Selkoe, Soluble oligomers of the amyloid β-protein (2011)
- Lambert et al., Diffusible, nonfibrillar ligands derived from Aβ1-42 (1998)
- Walsh et al., Naturally secreted oligomers of amyloid β-protein (2002)
- Krafft et al., The role of amyloid β oligomers in Alzheimer's disease (1989)
- Hill et al., Insights into Aβ oligomer neurotoxicity (2008)
- Haass & Selkoe, Soluble amyloid β aggregate physiology (2012)
- Benilova et al., The toxic Aβ oligomer and Alzheimer's disease (2010)
- Roychaudhuri et al., Aβ oligomers: where they come from (2013)
- Oda et al., Clusterin (ApoJ) sequesters toxic Aβ oligomers (2003)
- Li et al., Soluble Aβ oligomers inhibit LTP (2012)
- Tomiyama et al., A mouse model of Aβ oligomers (2010)
- Mucke, Alzheimer's disease: can removing Aβ oligomers restore function? (2011)
- Lekmine et al., Antibody-based therapeutics targeting Aβ oligomers (2013)
- Ivanova et al., Aβ oligomer structural diversity (2021)
- Chen et al., Aβ oligomer-specific antibodies in AD therapy (2017)
- Swanson et al., Lecanemab: an anti-Aβ antibody for early AD (2023)
- Mintun et al., Donanemab in early Alzheimer's disease (2021)
- Cullen et al., Soluble aggregates as a therapeutic target in AD (2022)